Unum Therapeutics (UNUM) plans to raise $75 million in an initial public offering on Thursday, March 29th, IPO Scoop reports. The company plans to issue 5,800,000 shares at a price of $12.00-$14.00 per share.
In the last twelve months, Unum Therapeutics generated $8.4 million in revenue and had a net loss of $25.6 million. Unum Therapeutics has a market-cap of $384.6 million.
Morgan Stanley and Cowen acted as the underwriters for the IPO and SunTrust Robinson Humphrey and Wedbush Securities were co-managers.
Unum Therapeutics provided the following description of their company for its IPO: “We are a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient’s immune system to cure cancer. Our proprietary technology, called antibody-coupled T cell receptor (ACTR), is a universal, engineered cell therapy that is intended to be used in combination with a wide range of tumor-specific antibodies to target different tumor types. Our product candidates are composed of ACTR T cells co-administered with approved and commercially available antibodies or antibodies in preclinical or clinical development. “.
Unum Therapeutics was founded in 2014 and has 53 employees. The company is located at 200 Cambridge Park Drive, Suite 3100, Cambridge, MA 02140, US and can be reached via phone at (617) 945-5576 or on the web at http://www.unumrx.com.
Receive News & Ratings for Unum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.